



United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/771,337	02/05/2004	Fumihiko Yokoya	25908	3930
20529 7:	590 03/20/2006		EXAMINER	
NATH & ASSOCIATES			WHALEY, PABLO S	
112 South West Street			ART UNIT	PAPER NUMBER
Alexandria, VA 22314			1631	TALER NOMBER
			DATE MAILED: 03/20/2000	5

Please find below and/or attached an Office communication concerning this application or proceeding.

	Application No.	Applicant(s)	·· · · · · · · · · · · · · · · · · · ·			
	10/771,337	YOKOYA ET AL.				
Office Action Summary	Examiner	Art Unit				
	Pablo Whaley	1631				
The MAILING DATE of this communication app Period for Reply	ears on the cover sheet wit	h the correspondence ad	dress			
A SHORTENED STATUTORY PERIOD FOR REPLY WHICHEVER IS LONGER, FROM THE MAILING DA - Extensions of time may be available under the provisions of 37 CFR 1.13 after SIX (6) MONTHS from the mailing date of this communication. - If NO period for reply is specified above, the maximum statutory period v - Failure to reply within the set or extended period for reply will, by statute, Any reply received by the Office later than three months after the mailing earned patent term adjustment. See 37 CFR 1.704(b).	ATE OF THIS COMMUNIC 36(a). In no event, however, may a rewill apply and will expire SIX (6) MONT, cause the application to become ABA	ATION. ply be timely filed HS from the mailing date of this country (35 U.S.C. § 133).				
Status						
1) Responsive to communication(s) filed on						
	action is non-final.					
3) Since this application is in condition for allowar		rs, prosecution as to the	merits is			
	closed in accordance with the practice under <i>Ex parte Quayle</i> , 1935 C.D. 11, 453 O.G. 213.					
Disposition of Claims	, , ,	,				
4)⊠ Claim(s) <u>1-9</u> is/are pending in the application.						
	4a) Of the above claim(s) is/are withdrawn from consideration.					
5) Claim(s) is/are allowed.						
6) Claim(s) is/are rejected.						
7) Claim(s) is/are objected to.						
8) Claim(s) 1-9 are subject to restriction and/or el	ection requirement.					
Application Papers						
9) The specification is objected to by the Examine	r.					
10) The drawing(s) filed on is/are: a) acce		v the Examiner.				
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).						
Replacement drawing sheet(s) including the correct	ion is required if the drawing(s	s) is objected to. See 37 CF	R 1.121(d).			
11)☐ The oath or declaration is objected to by the Ex	aminer. Note the attached	Office Action or form PT	O-152.			
Priority under 35 U.S.C. § 119	•					
12) Acknowledgment is made of a claim for foreign a) All b) Some * c) None of: 1. Certified copies of the priority documents 2. Certified copies of the priority documents 3. Copies of the certified copies of the prior application from the International Bureau * See the attached detailed Office action for a list	s have been received. s have been received in Ap ity documents have been r ı (PCT Rule 17.2(a)).	plication No eceived in this National	Stage			
Attachment(s) 1) Notice of References Cited (PTO-892) 2) Notice of Draftsperson's Patent Drawing Review (PTO-948) 3) Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08) Paper No(s)/Mail Date		/Mail Date ormal Patent Application (PTC)-152)			
	· -	-				

DETAILED ACTION

Election/Restrictions

Restriction to one of the following inventions is required under 35 U.S.C. 121:

Group I: Claims 1-8 drawn to a gene panel and a method of producing a gene panel, classified in class 702, subclass 019. If this Group is elected, then the below

summarized specie election is also required.

Group II: Claim 9 drawn to a method for screening a drug related to hepatic stellate cell activation, classified in class 702, subclass 019. If this Group is elected, then the below

summarized specie election is also required.

The inventions are distinct and divergent, each from the other because of the following reasons:

The invention of Group I and Group II are unrelated if it can be shown that they are not disclosed as capable of use together and they have different modes of operation, different functions, or different effects (MPEP § 806.04, MPEP § 808.01). In the instant case, the inventions of Group I and Group II have different effects. Group I is drawn to a gene panel and the related method for producing a gene panel, whereas Group II is drawn to a method for screening a drug related to hepatic stellate cell activation. Furthermore, the gene panel of Group I is not limited to drug screening applications, and therefore can be used for other applications (i.e. mutation identification, etc.). Therefore, the burden of search is maintained as the examination process requires a search of non-patent literature, U.S. patent publications, U.S. patents, as well as foreign patent literature.

SPECIE ELECTION REQUIREMENT FOR GROUP

This application contains claims directed to patentably distinct species of the claimed invention. If Group I is elected, the applicant is further required to make the following specie election for purposes of examination:

Specie A: Species of genes are cited in claim 5, which are generally separately classified and published, and thus document undue search burden if searched together. It is recognized that claim 5 limits an expression profile to comprise "at least five kinds of genes", however, for purposes of facilitating search and initial examination, applicants are required to elect ONE gene from those listed in Tables 1-4.

Applicant is required under 35 U.S.C. 121 to elect a single disclosed species from specie A for prosecution on the merits to which the claims shall be restricted if no generic claim is finally held to be allowable. Currently, claims 1-4 are generic to the above species.

Applicant is advised that a reply to this requirement must include an identification of the species that is elected consonant with this requirement, and a listing of all claims readable thereon, including any claims subsequently added. An argument that a claim is allowable or that all claims are generic is considered nonresponsive unless accompanied by an election.

Upon the allowance of a generic claim, applicant will be entitled to consideration of claims to additional species which are written in dependent form or otherwise include all the limitations of an allowed generic claim as provided by 37 CFR 1.141. If claims are added after the election, applicant must indicate which are readable upon the elected species. MPEP § 809.02(a).

Should applicant traverse on the ground that the species are not patentably distinct, applicant should submit evidence or identify such evidence now of record showing the species to be obvious variants or clearly admit on the record that this is the case. In either instance, if the examiner finds one of the inventions unpatentable over the prior art, the evidence or admission may be used in a rejection under 35 U.S.C. 103(a) of the other invention.

Because these inventions are distinct for the reasons given above and have acquired a separate status in the art because of their recognized divergent subject matter, restriction for examination purposes as indicated is proper.

Applicant is advised that the reply to this requirement to be complete must include an election of the invention to be examined even though the requirement be traversed (37 CFR 1.143).

Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a request under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(i).

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Pablo Whaley whose telephone number is (571)272-4425. The examiner can normally be reached on 9:30am through 6pm.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Ardin Marschel can be reached on (571)272-0718. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Application/Control Number: 10/771,337

Art Unit: 1631

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

i

MARJORIE A. MORAN PRIMARY EXAMINER

3/15/04

Page 5